Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

GLP-1 receptor agonists (like Wegovy and Mounjaro) have gained global attention for their ability to help people shed significant weight. These weight loss medications, administered via injections ...

and the use of weight loss medications has become more prevalent. Hy-Vee Dietitian Hannah Anderson reviews GLP-1 receptor agonists (Ozempic, Wegovy and Rybelsus) and the importance of evidence ...

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Among patients with diabetes, the use of GLP-1 RAs compared with standard care is associated with a reduced risk for neurocognitive and cardiometabolic disorders, and with an increased risk for ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...